POMALIDOMIDE CAP,ORAL
Clinical Criteria Summary
Exclusion Criteria
- Absolute neutrophil count (ANC) < 500/mm3
- Hemoglobin < 8 g/dL; Must transfuse to hemoglobin above 8 gm/dL prior to therapy initiation
- Platelet count < 50,000/mm3
- Eastern Cooperative Oncology Group performance status > 2
- Patient has not been screened for Hepatitis B Virus
- Active or uncontrolled infection
- Known pregnancy
- Lactating
Inclusion Criteria
- Relapsed or refractory multiple myeloma, following at least 2 lines of therapy that included lenalidomide and a proteasome inhibitor
- Diagnosis of Kaposi sarcoma
Additional Inclusion Criteria
- Care is provided by a VA or VA Community Care hematology/oncology provider
- Goals of care and role of Palliative Care consult have been discussed and documented
- Venous thromboembolism (VTE) risk scoring (i.e. SAVED, IMPEDE) performed for consideration of VTE prophylaxis
REMS & Pregnancy Safety Requirements
- Patients who can become pregnant and patients with partners who can become pregnant must comply with pregnancy testing and contraception requirements for pomalidomide under the POMALYST REMS program